The majority of inhibitory antibodies are directed at either the A2 or C2 domains of fVIII in either congenital or acquired hemophilia A. [12] Typically, congenital hemophiliacs have a polyclonal response with antibodies recognizing both the A2 and C2 domains, whereas acquired hemophilia patient antibodies typically recognize more limited B cell epitopes consisting of either anti-A2 or anti-C2 antibodies, but not both. The gene discussed is F8; the disease is hemophilia A.